Suryavanshi, SantoshAnderson, KodyJadhav, ShwetaLichtarge, OlivierMcConnell, Bradley K.2018-02-232018-02-232017http://hdl.handle.net/10657/2340mAKAP polymorphisms may pre-dispose humans to CVDs by altering cAMP/PKA signaling in the heart. PKA-mAKAP interaction modulators can be developed as therapeutic target to augment current treatment of CVDs. This project was completed with contributions from Alexei Degterev from the Department of Developmental, Molecular and Chemical Biology, School of Medicine, Tufts University, Boston.en-USPoster